$0.00
Register for Meetings
“In The News” & “Cardiovascular Marketplace” Content Access
Listen to Podcasts
Watch On-Demand Content
CardioTube Access
Access to Recorded Live Broadcasts from CRTvirtual Meetings, DMV, & Cath Conference
Access Recorded Interviews
Download PPT Slide Decks
Already have an account? Login Now
$650 Annually
Complimentary subscription to electronic version of the CRM Journal
Access to CRT Meeting Registration Discounts
CRT Premium Content, including on-demand videos and presentation downloads
Nathan Gray, CRTonline.org
Mavacamten significantly reduced the number of obstructive hypertrophic cardiomyopathy (oHCM) patients meeting guideline criteria for septal reduction therapy (SRT) after 16 weeks, new trial data reveal.
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details